Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

1.66 EUR

+8.36 %

5,659 following
Corporate customer

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+8.36 %
-28.45 %
-41.55 %
-55.97 %
-59.81 %
-59.01 %
-56.71 %
-83.56 %
-63.76 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
35.61M EUR
Turnover
196.73K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
07.05.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8.
2026

Interim report Q2'26

6.11.
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Youtube Optomed US. Introduction video for the Lumo camera. Looks like it was posted 2 weeks ago. It really is …as easy as can be … as fast as can be​
13 hours ago
by j.sälli
24
Market winners and other fast-growing companies that improve their performance every year are always of interest to buyers. On the other hand, losers like Optomed are generally not wanted as acquisitions in growth sectors. If you were on the other side of the table considering M&...
yesterday
by Pohjolan Eka
24
Lumo is being tested in the US. “Implementing Point-of-Care Diabetic Retinopathy Screening at a Free Community Clinic” https://institutionalrepository.aah.org/cgi/viewcontent.cgi?article=2448&context=allother
11 hours ago
by Sheikki
21
If Optomed maintains its guidance and achieves cash flow neutrality by the end of the year, we can expect quite a ride in H2/2026. Q3 will likely still be soft in terms of the top line (CAPEX is catching up, but hasn’t reached it yet), but if Aurora AEYE continues with 30% YoY growth...
yesterday
by Dr.Feelgood
17
https://www.redeye.se/research/1166046/optomed-q1-interview-expecting-normalised-sales-in-upcoming-quarters?utm_source=interview&utm_medium=email Redeye interview.
yesterday
by Tobias
14
Listened. Repeating the same points as on Inderes, but more concisely. Confident that the guidance will hold, meaning growth based on Aurora/AEYE’s performance. It’s interesting that if this happens, AEYE is “pure margin” because only their own share of AEYE’s sales is recorded. ...
yesterday
by Puutaheinää
10
A Digital Health Finland publication showcasing Finnish health technology and digital health solutions. Optomed is also included. digifinland.fi DHFi_Agetech_-4-2026.pdf 1781.63 KB
yesterday
by Artoh1
9
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.